Engineered immune cells take on advanced liver cancer in first human trial
NCT ID NCT06676982
First seen Jan 09, 2026 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This early-stage trial is testing a new treatment called CNCT19 CAR-T cells for people with advanced liver cancer that cannot be removed by surgery or has come back after other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goals are to check safety and find the best dose, with only 12 participants enrolled so far.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital, Medical College of Zhejiang University
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CNCT19 CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced liver cancer that is hard to treat with standard methods.
What could go wrong
This is a very early phase 1 trial with only 12 people, so it is mainly checking safety and dosing. It may not show strong anti-cancer effects, and CAR-T therapy can cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.